27 results on '"Tassinari, Elisa"'
Search Results
2. The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study
- Author
-
Mollica, Veronica, Rizzo, Alessandro, Marchetti, Andrea, Tateo, Valentina, Tassinari, Elisa, Rosellini, Matteo, Massafra, Raffaella, Santoni, Matteo, and Massari, Francesco
- Published
- 2023
- Full Text
- View/download PDF
3. Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study
- Author
-
Rizzo, Alessandro, Mollica, Veronica, Tateo, Valentina, Tassinari, Elisa, Marchetti, Andrea, Rosellini, Matteo, De Luca, Raffaele, Santoni, Matteo, and Massari, Francesco
- Published
- 2023
- Full Text
- View/download PDF
4. Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
- Author
-
Santoni, Matteo, Rizzo, Alessandro, Kucharz, Jakub, Mollica, Veronica, Rosellini, Matteo, Marchetti, Andrea, Tassinari, Elisa, Monteiro, Fernando Sabino Marques, Soares, Andrey, Molina-Cerrillo, Javier, Grande, Enrique, Battelli, Nicola, and Massari, Francesco
- Published
- 2023
- Full Text
- View/download PDF
5. Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis
- Author
-
Rosellini, Matteo, Mollica, Veronica, Marchetti, Andrea, Coluccelli, Sara, Giunchi, Francesca, Tassinari, Elisa, Ricci, Costantino, Fiorentino, Michelangelo, Tallini, Giovanni, De Biase, Dario, and Massari, Francesco
- Published
- 2024
- Full Text
- View/download PDF
6. TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab.
- Author
-
Mollica, Veronica, Tassinari, Elisa, Santoni, Matteo, Marchese, Paola Valeria, Giunchi, Francesca, Maloberti, Thais, Tateo, Valentina, Ricci, Costantino, Rosellini, Matteo, Marchetti, Andrea, Fiorentino, Michelangelo, Biase, Dario De, and Massari, Francesco
- Published
- 2024
- Full Text
- View/download PDF
7. Safety issues in nutraceutical exploitation of Chlorella vulgaris, Arthrospira Platensis and Scenedesmus sp. microalgae
- Author
-
Davani, Lara, Tassinari, Elisa, Chiaberge, Stefano, Siviero, Andrea, Serbolisca, Luca, Tumiatti, Vincenzo, Terenzi, Cristina, De Simone, Angela, Andrisano, Vincenza, and Montanari, Serena
- Published
- 2023
- Full Text
- View/download PDF
8. First in Class Dual Non-ATP-Competitive Glycogen Synthase Kinase 3β/Histone Deacetylase Inhibitors as a Potential Therapeutic to Treat Alzheimer's Disease.
- Author
-
Santini, Alan, Tassinari, Elisa, Poeta, Eleonora, Loi, Manuela, Ciani, Elisabetta, Trazzi, Stefania, Piccarducci, Rebecca, Daniele, Simona, Martini, Claudia, Pagliarani, Barbara, Tarozzi, Andrea, Bersani, Matteo, Spyrakis, Francesca, Danková, Daniela, Olsen, Christian A., Soldati, Roberto, Tumiatti, Vincenzo, Montanari, Serena, De Simone, Angela, and Milelli, Andrea
- Published
- 2024
- Full Text
- View/download PDF
9. Integrating a quinone substructure into histone deacetylase inhibitors to cope with Alzheimer's disease and cancer.
- Author
-
Guardigni, Melissa, Greco, Giulia, Poeta, Eleonora, Santini, Alan, Tassinari, Elisa, Bergamini, Christian, Zalambani, Chiara, De Simone, Angela, Andrisano, Vincenza, Uliassi, Elisa, Monti, Barbara, Bolognesi, Maria Laura, Fimognari, Carmela, and Milelli, Andrea
- Published
- 2024
- Full Text
- View/download PDF
10. Prognostic and predictive factors to nivolumab in patients with metastatic renal cell carcinoma: a single center study
- Author
-
Mollica, Veronica, Rizzo, Alessandro, Tassinari, Elisa, Giunchi, Francesca, Schiavina, Riccardo, Fiorentino, Michelangelo, Brunocilla, Eugenio, Ardizzoni, Andrea, and Massari, Francesco
- Published
- 2021
- Full Text
- View/download PDF
11. Appropriateness of Mini-Invasive Approaches for Nausea and Vomiting Refractory to Medical Therapy in Palliative Care Setting: A Case Report.
- Author
-
Casadio, Chiara, Tassinari, Elisa, Carloni, Riccardo, Rossi, Romina, Tenti, Maria Valentina, Fabbri, Laura, and Maltoni, Marco
- Subjects
- *
PALLIATIVE treatment , *NAUSEA , *CANCER patients , *VOMITING , *DRUG therapy - Abstract
Introduction: Nausea and vomiting are frequent multifactorial symptoms in oncological patients. These manifestations, mainly affecting the advanced disease stages, may lead to existential, psychological, and physical suffering, with a negative impact on the quality of life (QoL) of the individual and his family. The medical approach makes use of a wide range of drugs, with different antiemetic potency and various mechanisms of action, taking into account the etiology and the patient's response to the different therapeutic strategies. In recent years, in addition to pharmacological treatments, some endoscopic procedures have been integrated into clinical practice as promising palliative approaches. Case Presentation: Herein, we describe and discuss a case of a 64-year-old female affected by advanced stage pancreatic adenocarcinoma, in which different techniques – both medical and endoscopic – have been used to approach a refractory symptomatology with a negative impact on the patient's QoL. In the context of a multidisciplinary approach in primary palliative care, a tailored intervention encompassing invasive methods for palliative purposes, may be considered adequate and appropriate when the prognostic expectation and the physical functionality indices allow it. Conclusion: Minimally invasive palliative interventions should be offered to patients with advanced cancer when symptoms become refractory to standard medical therapies, as part of the holistic approach in modern treatments. Therefore, the integration of an early palliative approach into the patient's therapeutic path becomes essential for the management of all the individual's needs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. From Monoamine Oxidase Inhibition to Antiproliferative Activity: New Biological Perspectives for Polyamine Analogs.
- Author
-
Nordio, Giulia, Piazzola, Francesco, Cozza, Giorgio, Rossetto, Monica, Cervelli, Manuela, Minarini, Anna, Basagni, Filippo, Tassinari, Elisa, Dalla Via, Lisa, Milelli, Andrea, and Di Paolo, Maria Luisa
- Subjects
POLYAMINES ,MONOAMINE oxidase ,PROSTATE cancer ,OXIDASES ,NEUROLOGICAL disorders ,NEURODEGENERATION - Abstract
Monoamine oxidases (MAOs) are well-known pharmacological targets in neurological and neurodegenerative diseases. However, recent studies have revealed a new role for MAOs in certain types of cancer such as glioblastoma and prostate cancer, in which they have been found overexpressed. This finding is opening new frontiers for MAO inhibitors as potential antiproliferative agents. In light of our previous studies demonstrating how a polyamine scaffold can act as MAO inhibitor, our aim was to search for novel analogs with greater inhibitory potency for human MAOs and possibly with antiproliferative activity. A small in-house library of polyamine analogs (2–7) was selected to investigate the effect of constrained linkers between the inner amine functions of a polyamine backbone on the inhibitory potency. Compounds 4 and 5, characterized by a dianiline (4) or dianilide (5) moiety, emerged as the most potent, reversible, and mainly competitive MAO inhibitors (Ki < 1 μM). Additionally, they exhibited a high antiproliferative activity in the LN-229 human glioblastoma cell line (GI
50 < 1 μM). The scaffold of compound 5 could represent a potential starting point for future development of anticancer agents endowed with MAO inhibitory activity. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
13. Prostate cancer and novel pharmacological treatment options–what's new for 2022?
- Author
-
Marchetti, Andrea, Tassinari, Elisa, Rosellini, Matteo, Rizzo, Alessandro, Massari, Francesco, and Mollica, Veronica
- Subjects
DRUG therapy ,DOCETAXEL ,PROSTATE cancer ,ANDROGEN receptors ,ANDROGEN deprivation therapy ,THERAPEUTICS ,BONE metastasis - Abstract
Androgen deprivation therapy (ADT) plus Androgen Receptor Target Agents (ARTAs) or docetaxel are the actual standard of care in prostate cancer (PC). Several therapeutic options are available for pretreated patients: cabazitaxel, olaparib, and rucaparib for BRCA mutations, Radium-223 for selected patients with symptomatic bone metastasis, sipuleucel T, and 177 LuPSMA-617. This review the new potential therapeutic approaches and the most impacting recent published trials to provide an overview on the future management of PC. Currently, there is a growing interest in the potential role of triplet therapies encompassing ADT, chemotherapy, and ARTAs. These strategies, explored in different settings, appeared to be particularly promising in metastatic hormone-sensitive PC. Recent trials investigating ARTAs plus poly(adenosine diphosphate–ribose) polymerase (PARPi) inhibitor provided helpful insights for patients with metastatic castration resistant disease, regardless of homologous recombination genes status. Otherwise, the publication of the complete data is awaited, and more evidence is required. In advanced settings, several combination approaches are under investigation, to date with contradictory results, such as immunotherapy plus PARPi or chemotherapy. The radionuclide
177 Lu-PSMA-617 proved successful outcomes in pretreated mCRPC patients. Additional studies will better clarify the appropriate candidates to each strategy and the correct treatments' sequence. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
14. Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis.
- Author
-
Rizzo, Alessandro, Nuvola, Giacomo, Palmiotti, Gennaro, Ahcene-Djaballah, Selma, Mollica, Veronica, Rosellini, Matteo, Marchetti, Andrea, Nigro, Maria Concetta, Tassinari, Elisa, Macrini, Sveva, and Massari, Francesco
- Published
- 2023
- Full Text
- View/download PDF
15. The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy.
- Author
-
De Giglio, Andrea, Tassinari, Elisa, Zappi, Arianna, Di Federico, Alessandro, Lenzi, Barbara, Sperandi, Francesca, Melotti, Barbara, Gelsomino, Francesco, Maltoni, Marco, and Ardizzoni, Andrea
- Subjects
- *
THERAPEUTIC use of antineoplastic agents , *LUNG cancer , *IMMUNE checkpoint inhibitors , *RETROSPECTIVE studies , *CANCER patients , *RISK assessment , *PALLIATIVE treatment , *IMMUNOTHERAPY , *PROPORTIONAL hazards models ,MORTALITY risk factors - Abstract
Simple Summary: The acceptable safety profile of immunotherapy may affect the risk-benefit ratio analysis of treatment prescription near the late stage of life for advanced non-small cell lung cancer patients. The aim of our retrospective study was to describe the clinical characteristics of patients receiving immunotherapy in the last stages of life and to evaluate the accuracy in predicting short-time mortality of LIPI and PaPwCPS scores. Our findings demonstrated an increased tendency in immunotherapy use in during the last month of life. In this context, a laboratory and clinical score such as the PaPwCPS may improve the physician's ability to predict early mortality for immunotherapy-eligible patients. Background: An acceptable risk-benefit ratio may encourage the prescription of immune checkpoint inhibitors (ICI) near the late stage of life. The lung immune prognostic index (LIPI) was validated in advanced non-small cell lung cancer (NSCLC) patients treated with ICIs. The palliative prognostic (PaP) score without clinical prediction of survival (PaPwCPS) predicts early mortality probability in terminal cancer patients. Methods: We performed a retrospective study including 182 deceased advanced NSCLC patients, treated with single-agent ICI at our Institution. Two prognostic categories of high and low mortality risk were identified through ROC curve analysis for PaPwCPS and LIPI scores. Results: Most were >65 years of age (68.3%) and received second-line ICI (61.2%). A total of 29 (15.9%) and 131 (72.0%) patients died within 30 and 90 days from treatment start, respectively. A total of 81 patients (44.5%) received ICI during the last month of life. Baseline PaPwCPS and LIPI scores were assessable for 78 patients. The AUC of ROC curves was significantly increased for PaPwCPS as compared with LIPI score for both 30-day and 90-day mortality. A high PaPwCPS score was associated in multivariate analysis with increased 30-day (HR 2.69, p = 0.037) and 90-day (HR 4.01, p < 0.001) mortality risk. A high LIPI score was associated with increased 90-day mortality risk (p < 0.001). Conclusion: We found a tendency towards ICI prescription near the late stage of life. The PaPwCPS score was a reliable predictor of 30- and 90-day mortality. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers.
- Author
-
Marchese, Paola Valeria, Mollica, Veronica, Tassinari, Elisa, De Biase, Dario, Giunchi, Francesca, Marchetti, Andrea, Rosellini, Matteo, Fiorentino, Michelangelo, and Massari, Francesco
- Abstract
The reactivation of telomerase represents a key moment in the carcinogenesis process. Mutations in the central promoter region of the telomerase reverse transcriptase (TERT) gene cause telomerase reactivation in approximately 90% of solid tumors. In some of these, its prognostic and predictive role in response to treatments has already been demonstrated, in others (such as tumors of the genitourinary tract like urothelial carcinoma) data are controversial and the research is still ongoing. In the future, TERT promoter mutations and telomerase activity could have diagnostic, prognostic, and therapeutic applications in many types of cancer. We performed a review the literature with the aim of describing the current evidence on the prognostic and predictive role of TERT promoter mutations. In some tumor types, TERT promoter mutations have been associated with a worse prognosis and could have a potential value as biomarkers to guide therapeutic decisions. Mutations in TERT promoter seems to make the tumor particularly immunogenic and more responsive to immunotherapy, although data is controversial. We described the role of TERT promoter mutations in solid tumors with a particular focus in genitourinary cancers, considering their frequency in this tract. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
17. Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial
- Author
-
Rosellini, Matteo, Tassinari, Elisa, Marchetti, Andrea, Mollica, Veronica, and Massari, Francesco
- Published
- 2024
- Full Text
- View/download PDF
18. Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study.
- Author
-
Rizzo, Alessandro, Mollica, Veronica, Marchetti, Andrea, Nuvola, Giacomo, Rosellini, Matteo, Tassinari, Elisa, Molina-Cerrillo, Javier, Myint, Zin W., Buchler, Tomas, Monteiro, Fernando Sabino Marques, Grande, Enrique, Santoni, Matteo, and Massari, Francesco
- Subjects
PROGRAMMED cell death 1 receptors ,ADJUVANT chemotherapy ,MEDICAL databases ,ONLINE information services ,META-analysis ,IMMUNE checkpoint inhibitors ,MEDICAL information storage & retrieval systems ,CONFIDENCE intervals ,SYSTEMATIC reviews ,CANCER relapse ,CANCER patients ,SURVIVAL analysis (Biometry) ,TUMORS ,MEDLINE ,IMMUNOTHERAPY - Abstract
Simple Summary: Despite a significant improvement in clinical outcomes and the emergence of novel and potentially curative strategies, a noticeable number of oncological patients witness a disease relapse after surgery. Adjuvant treatments have been developed to reduce the risk of recurrence and gain survival benefits for these patients. The aim of this meta-analysis was to explore the impact of adjuvant PD-1/PD-L1 inhibitors on relapse-free survival in cancer patients with many solid tumors. We confirmed that PD-1/PD-L1 inhibitors may reduce the risk of relapse in many tumor types, compared to control treatments. Moreover, we showed that the benefit was consistent in subgroups divided according to gender and age. Background: Adjuvant treatment has always been a cornerstone in the therapeutic approach of many cancers, considering its role in reducing the risk of relapse and, in some cases, increasing overall survival. Adjuvant immune checkpoint inhibitors have been tested in different malignancies. Methods: We performed a meta-analysis aimed to explore the impact of adjuvant PD-1 and PD-L1 inhibitors on relapse-free survival (RFS) in cancer patients enrolled in randomized controlled clinical trials. We retrieved all phase III trials published from 15 June 2008 to 15 May 2022, evaluating PD-1/PD-L1 inhibitors monotherapy as an adjuvant treatment by searching on EMBASE, Cochrane Library, and PubMed/ Medline, and international oncological meetings' abstracts. The outcome of interest was RFS. We also performed subgroup analyses focused on age and gender. Results: Overall, 8 studies, involving more than 6000 patients, were included in the analysis. The pooled results highlighted that the use of adjuvant PD-1/PD-L1 inhibitors may reduce the risk of relapse compared to control treatments (hazard ratio, 0.72; 95% confidence intervals, 0.67–0.78). In addition, the subgroup analyses observed that this benefit was consistent in different patient populations, including male, female, younger, and older patients. Conclusions: Adjuvant anti-PD-1/PD-L1 treatment is associated with an increased RFS in the overall population and in subgroups divided according to age and gender. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
19. Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis.
- Author
-
Mollica, Veronica, Massari, Francesco, Andrini, Elisa, Rosellini, Matteo, Marchetti, Andrea, Nuvola, Giacomo, Tassinari, Elisa, Lamberti, Giuseppe, and Campana, Davide
- Subjects
BLADDER cancer ,NEUROENDOCRINE cells ,NEUROENDOCRINE system ,CANCER treatment ,PROGNOSIS - Abstract
Background: High-grade neuroendocrine carcinoma (NEC) is a rare and aggressive variant of bladder cancer. Considering its rarity, its therapeutic management is challenging and not standardized. Methods: We analyzed data extracted from the Surveillance, Epidemiology, and End Results (SEER) registry to evaluate prognostic factors for high-grade NEC of the bladder. Results: We extracted data on 1134 patients: 77.6% were small cell NEC, 14.6% were NEC, 5.5% were mixed neuro-endocrine non-neuroendocrine neoplasia, and 2.3% were large cell NEC. The stage at diagnosis was localized for 45% of patients, lymph nodal disease (N+M0) for 9.2% of patients, and metastatic disease for 26.1% of patients. The median overall survival (OS) was 12 months. Multivariate analysis detected that factors associated with worse OS were age being >72 years old (HR 1.94), lymph nodal involvement (HR 2.01), metastatic disease (HR 2.04), and the size of the primary tumor being >44.5 mm (HR 1.80). In the N0M0 populations, the size of the primary tumor being <44.5 mm, age being <72 years old, and major surgery were independently associated with a lower risk of death. In the N+M0 group, the size of the primary lesion was the only factor to retain an association with OS. Conclusions: Our SEER database analysis evidenced prognostic factors for high-grade NEC of the bladder that are of pivotal relevance to guide treatment and the decision-making process. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy.
- Author
-
Tassinari, Elisa, Mollica, Veronica, Nuvola, Giacomo, Marchetti, Andrea, Rosellini, Matteo, and Massari, Francesco
- Subjects
TRANSITIONAL cell carcinoma ,FIBROBLAST growth factor receptors ,CELL adhesion molecules ,IMMUNE checkpoint inhibitors ,ANTIBODY-drug conjugates - Abstract
Urothelial carcinoma (UC) is a frequently diagnosed tumor and an important cause of cancer deaths worldwide. Until a few years ago, despite the unquestioned role of platinum-based chemotherapy, therapeutic choices beyond the first line were limited and related to unsatisfactory outcomes. Metastatic UC has always been associated with a poor prognosis, with overall survival only slightly above a year. In the recent past, huge progress has been made in our understanding of the molecular and genomic disease characteristics, to enable stratification of patients in terms of prognosis and treatment responses. Unfortunately, we still do not have the perfect combination of clinical biomarkers to tailor the optimal treatment for each patient, despite making several efforts in this direction. The therapeutic arsenal has been augmented by immune checkpoint inhibitors (ICIs), which nowadays represent the backbone of the second-line setting. Equally revolutionary was the FDA's approval of erdafitinib, a potent fibroblast growth factor receptor (FGFR) inhibitor, the use of which is reserved for patients whose tumor harbors specific FGF pathway alterations. Recently, the therapeutic landscape of metastatic UC has been enhanced by the introduction of novel compounds, consisting of antibody–drug conjugates (ADCs). Enfortumab vedotin is an antibody targeting nectin-4, a cell adhesion molecule highly expressed in UC, conjugated to monomethyl auristatin E (MMAE), a microtubule-disrupting agent. Sacituzumab govitecan is a humanized monoclonal antibody targeting Trop-2, a transmembrane glycoprotein, conjugated to the active metabolite of irinotecan. These two compounds have received accelerated approval by the FDA in patients pretreated with platinum-based chemotherapy and immunotherapy. Several ongoing trials are investigating the role of ICIs combined with chemotherapy, antiangiogenic drugs, or other ICIs, as well as the efficacy of PARP inhibitors and target therapies, hoping to provide information for some important unmet needs. In this review, we aim to evaluate the current potential treatment options after first-line chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
21. Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw.
- Author
-
Mollica, Veronica, Nuvola, Giacomo, Tassinari, Elisa, Nigro, Maria Concetta, Marchetti, Andrea, Rosellini, Matteo, Rizzo, Alessandro, Errani, Costantino, and Massari, Francesco
- Subjects
THERAPEUTIC use of monoclonal antibodies ,PROSTATE tumors treatment ,OSTEONECROSIS ,ZOLEDRONIC acid ,BONE metastasis ,PROSTATE tumors ,DISEASE complications - Abstract
Introduction: Bone metastases are the most frequent site of secondary localization of prostate cancer (PCa) and are present in about 90% of cases of advanced disease. Consequently, an adequate management of bone involvement is of pivotal importance in the therapeutic approach and skeletal-related events (SREs) need to be closely monitored and promptly assessed and treated. Bone targeting agents (BTAs), consisting in bisphosphonates and denosumab, are an essential part of the treatment of metastatic prostate cancer that accompanies systemic treatments throughout the most part of the history of the disease. Activity and safety of bone targeting agents: These treatments are correlated to better outcomes in terms of reduction of SREs and, in metastatic castration resistant setting, of increased overall survival (OS), but several important adverse events have to be managed and prevented. Of these, osteonecrosis of the jaw (ONJ) is extremely invalidating and should be managed with a special attention. Discussion: The role of BTAs in prostate cancer is pivotal throughout many stages of the disease, but several toxicities should be quickly recognized and treated. We aim at recollecting evidence on clinical benefit of BTAs, common and specific toxicities, and explore the pathophysiology and clinical aspects of osteonecrosis of the jaw. We present a review of the literature to report the role of the different types of bone targeting agents in the management of prostate cancer with bone metastases with a particular focus on common toxicities and ONJ to recollect current evidences on the activity of these compounds and the correct management of their adverse events. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
22. PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What's Now, What's New, and What's Coming?
- Author
-
Marchetti, Andrea, Rosellini, Matteo, Nuvola, Giacomo, Tassinari, Elisa, Mollica, Veronica, Rizzo, Alessandro, Santoni, Matteo, Cimadamore, Alessia, Farolfi, Andrea, Montironi, Rodolfo, Fanti, Stefano, and Massari, Francesco
- Subjects
MICROMETASTASIS ,ANTINEOPLASTIC agents ,PATIENT-centered care ,METABOLIC disorders ,ANDROGEN receptors ,NUCLEAR medicine ,DNA repair ,PROSTATE tumors ,ENZYME inhibitors ,LIGANDS (Biochemistry) ,PHARMACODYNAMICS - Abstract
Simple Summary: Prostate cancer still represents an important health problem in men, considering its high frequency. Over the last decade, novel treatment options have emerged, leading to notable clinical benefits. These recent scientific acquisitions are creating the basis to widen the treatment scenario of this tumor, evolving from targeting the androgen receptor axis or the traditional chemotherapy approach. In recent years, the advances in the knowledge on the molecular characteristics of prostate cancer is allowing to explore novel treatment scenarios. Furthermore, technological discoveries are widening diagnostic and treatment weapons at the clinician disposal. Among these, great relevance is being gained by PARP inhibitors and radiometabolic approaches. The result is that DNA repair genes need to be altered in a high percentage of patients with metastatic prostate cancer, making these patients optimal candidates for PARP inhibitors. These compounds have already been proved to be active in pretreated patients and are currently being investigated in other settings. Radiometabolic approaches combine specific prostate cancer cell ligands to radioactive particles, thus allowing to deliver cytotoxic radiations in cancer cells. Among these, radium-223 and lutetium-177 have shown promising activity in metastatic pretreated prostate cancer patients and further studies are ongoing to expand the applications of this therapeutic approach. In addition, nuclear medicine techniques also have an important diagnostic role in prostate cancer. Herein, we report the state of the art on the knowledge on PARP inhibitors and radiometabolic approaches in advanced prostate cancer and present ongoing clinical trials that will hopefully expand these two treatment fields. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
23. The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What's the Story Morning Glory?
- Author
-
Marchetti, Andrea, Rosellini, Matteo, Mollica, Veronica, Rizzo, Alessandro, Tassinari, Elisa, Nuvola, Giacomo, Cimadamore, Alessia, Santoni, Matteo, Fiorentino, Michelangelo, Montironi, Rodolfo, and Massari, Francesco
- Subjects
RENAL cell carcinoma ,CISPLATIN ,PROTEIN-tyrosine kinase inhibitors ,RENAL cancer ,PROGNOSIS ,MTOR inhibitors - Abstract
Non-clear cell renal cell carcinomas are a miscellaneous group of tumors that include different histological subtypes, each one characterized by peculiarity in terms of genetic alteration, clinical behavior, prognosis, and treatment response. Because of their low incidence and poor enrollment in clinical trials, alongside their heterogeneity, additional efforts are required to better unveil the pathogenetic mechanisms and, consequently, to improve the treatment algorithm. Nowadays, tyrosine kinase inhibitors, mTOR and MET inhibitors, and even cisplatin-based chemotherapy and immunotherapy are potential weapons that are still under evaluation in this setting. Various biomarkers have been evaluated for detecting progression and monitoring renal cell carcinoma, but more studies are necessary to improve this field. In this review, we provide an overview on the molecular characteristics of this group of tumors and the recently published trials, giving an insight into what might become the future therapeutic standard in this complex world of non-clear cell kidney cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Blessing or Curse? The Rise of Tourism‐Led Growth in Europe's Southern Periphery.
- Author
-
Bürgisser, Reto and Di Carlo, Donato
- Subjects
BLESSING & cursing ,EUROPEAN integration ,BALANCE of payments ,DEVALUATION of currency ,EUROZONE ,AUSTERITY ,TOURISM - Abstract
Despite being one of the world's major internationally traded services, tourism remains neglected within debates on European integration and growth models. We highlight the rise of tourism‐led growth in southern Europe and argue that the process of European integration has been a double‐edged sword, simultaneously incentivizing and forcing southern European economies to reap their comparative advantage in tourism. While European integration has created the preconditions for the expansion of intra‐European tourism, monetary integration pre‐empts macroeconomic management. Since the eurozone crisis, internal devaluation and fiscal austerity have suppressed the domestic growth drivers, inducing these governments towards an export‐led growth strategy. We document the emergence of unprecedented tourism‐related current account surpluses in southern Europe, driven strongly by tourism imports from the EMU core countries and the UK. Thus, while different export‐led growth strategies now coexist in the EMU, southern Europe's excessive reliance on international tourism for growth comes with severe pitfalls. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. Targeted industrial policy and government failures: insights from the South Korean experience.
- Author
-
Tassinari, Mattia, Barbieri, Elisa, Morleo, Giovanni, and Di Tommaso, Marco Rodolfo
- Abstract
Purpose: The purpose of this paper is to reflect on the efficiency and effectiveness of industrial policies by focusing on the peculiar experience of South Korea. It analyzes Korean structural change from a historical and empirical standpoint, highlighting industrial policy interventions involved in this process. The analysis presented offers important insights to inform the debate on the contemporary industrial policy, identifying specific elements and circumstances that can contribute to mitigate government failures and to improve the effectiveness of public action. Design/methodology/approach: The paper adopts a historical and empirical perspective. Concerning the empirical analysis, a composite indicator to assess the process of structural change of economies is presented. This methodology provides annual rankings based on the different economic relevance of the manufacturing sectors over the period 1963–2012. Findings: The paper shows that industrial policy has been extensively involved in South Korean structural development but public intervention interacted with several other factors, including gradual markets liberalization, education, societal and cultural characteristics and low level of income inequalities. As a result, economic development is conceived as systemic process, namely as the outcome of a balance in the roles played by government, markets and civil society. In this framework, government failures, as inability of the government to respond effectively and efficiently to the general interest of the society, are intimately inherent to the mechanisms that rule the relevant relationships within the system. Originality/value: In the post-crisis debate, very little attention has been devoted in academic and political debate to the ways to mitigate government failures. By analyzing the historical and recent Korean experience with industrial policy, the paper addresses an issue insufficiently analyzed offering an innovative contribution. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Institutional and economic transition in Vietnam: Analysing the heterogeneity in firms' perceptions of business environment constraints.
- Author
-
Angelino, Antonio, Tassinari, Mattia, Barbieri, Elisa, and Di Tommaso, Marco R
- Subjects
ECONOMIC expansion ,DISCRETE choice models ,BUSINESS conditions ,BUSINESS development ,RED tape - Abstract
Vietnam has experienced a gradual process of institutional transition combined with rapid economic growth since the Doi Moi reform in 1986. In recent years, the government has recognized the need to implement reforms to foster the development of favourable business environment conditions. In this scenario, however, the government seems to assume a uniform demand for business environment reforms, ignoring possible divergences in the constraints faced by different actors of the system. The aim of this paper is to analyse the heterogeneity in firms' perceptions of business environment constraints. Adopting discrete choice models on firm-level data and subjective assessments on business environment obstacles, we differentiate the nature and severity of firms' obstacles according to different characteristics of the enterprises, including the firm size, territorial localization and levels of performance and competitiveness. The study is useful as an informative base for defining public interventions calibrated on the different categories and needs of Vietnamese enterprises. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy.
- Author
-
Marchese, Paola Valeria, Mollica, Veronica, De Biase, Dario, Giunchi, Francesca, Tassinari, Elisa, Marchetti, Andrea, Rosellini, Matteo, Nuvola, Giacomo, Maloberti, Thais, Fiorentino, Michelangelo, and Massari, Francesco
- Subjects
- *
TRANSITIONAL cell carcinoma , *IMMUNE checkpoint inhibitors , *BRAF genes , *GENETIC mutation , *RITUXIMAB , *PROGRESSION-free survival , *SURVIVAL rate - Abstract
The therapeutic scenario of urothelial carcinoma is constantly expanding with the widening of the knowledge on molecular characteristics, thus claiming for the need of prognostic and predictive factors to guide treatment strategy. TERT promoter mutation is one of the most frequent genomic alterations in urothelial carcinoma and could present several implications, from diagnostic to prognostic or potentially even predictive. We performed a single-center retrospective analysis on patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor as second line of therapy to assess the status of the TERT promoter and the potential implication of its mutation on survival outcomes. We analyzed tissue samples from 11 patients with a next-generation sequencing multi-gene panel. The most frequently altered genes were TP53 (54.5%, n = 6) and TERT promoter (36.3%, n = 4). Other mutations found were BRAF, SMAD4, PIK3CA / PDGRFA. The only type of detected TERT promoter mutation was the c 0.124 C>T (n = 4/4, 100%). Of the 4 TERT mutated patients, 2 presented a co-mutation of TP53. Patients with TERT promoter mutation treated with immunotherapy presented a low median overall survival (16.5 months) and progression-free survival (3.8 months). Our hypothesis-generating analysis suggests that the presence of TERT promoter mutation could have a negative prognostic value and should be further evaluated in wider cohorts. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.